Human Phospholipase A2, membrane associated(PLA2G2A) ELISA kit

Instructions
Code CSB-EL018091HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name phospholipase A2, group IIA (platelets, synovial fluid)
Alternative Names EC 3.1.1.4 ELISA Kit; GIIC sPLA2 ELISA Kit; Group IIA phospholipase A2 ELISA Kit; membrane associated ELISA Kit; Modifier of MIN 1 mouse homolog ELISA Kit; MOM1 ELISA Kit; Non-pancreatic secretory phospholipase A2 ELISA Kit; NPS PLA2 ELISA Kit; NPS-PLA2 ELISA Kit; PA2GA_HUMAN ELISA Kit; Phosphatidylcholine 2-acylhydrolase 2A ELISA Kit; Phosphatidylcholine 2acylhydrolase ELISA Kit; Phospholipase A2 ELISA Kit; Phospholipase A2 group IIA (platelets, synovial fluid) ELISA Kit; Phospholipase A2 membrane associated ELISA Kit; Phospholipase A2 polypeptide B ELISA Kit; Phospholipase A2 synovial ELISA Kit; PLA2 ELISA Kit; PLA2B ELISA Kit; PLA2G2A ELISA Kit; PLA2L ELISA Kit; PLA2S ELISA Kit; PLAS1 ELISA Kit; RASF A ELISA Kit; sPLA2 ELISA Kit
Abbreviation PLA2G2A
Uniprot No. P14555
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 1.56 ng/mL-100 ng/mL
Sensitivity 0.39 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Metabolism
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human PLA2G2A in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %95
Range %90-100
1:2Average %89
Range %84-93
1:4Average %104
Range %100-110
1:8Average %93
Range %86-98
Recovery
The recovery of human PLA2G2A spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9085-94
EDTA plasma (n=4)9894-105
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1OD2AverageCorrected
1002.617 2.507 2.562 2.351
502.093 1.986 2.040 1.829
251.509 1.409 1.459 1.248
12.50.976 0.938 0.957 0.746
6.250.601 0.576 0.589 0.378
3.120.438 0.472 0.455 0.244
1.560.305 0.317 0.311 0.100
00.214 0.208 0.211
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 5-7 working days

Citations

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides
Gene References into Functions
  1. sPLA2 appears to play an important role in the pathogenesis of dengue. We found that sPLA2 activity was significantly higher in patients with dengue haemorrhagic fever when compared to those with dengue fever, during the first 120 h of clinical illness. PMID: 28250920
  2. The findings of this study showed that maslinic acid inhibit inflammatory effects induced by sPLA2-IIA, including foam cells formation and PGE2 production. PMID: 29872016
  3. High PLA2 activity is associated with West Nile virus infection. PMID: 29709018
  4. A lipidomics-based LC/MS assay was used to define the specificity of cPLA2, iPLA2, and sPLA2 toward a variety of phospholipids. A unique hydrophobic binding site for the cleaved fatty acid dominates each enzyme's specificity rather than its catalytic residues and polar headgroup binding site. PMID: 29342349
  5. demonstration of an independent association between early-stage atherosclerosis and increased levels of sPLA2-IIa, implying that increased sPLA2-IIa may have a role in early-stage atherosclerosis in MetS patients PMID: 27941821
  6. these results suggest that PLA2G2A polymorphisms are involved in the risk of developing metabolic syndrome and type 2 diabetes mellitus and are associated with subclinical atherosclerosis in this group of patients PMID: 27608594
  7. PLA2G2A has a previously undiscovered impact on insulin sensitivity and metabolism PMID: 28663239
  8. lipidomic analyses revealed that sequestration of PUFAs in LDs by sPLA2-induced TAG remodelling and retention of PUFAs in LDs by inhibition of ATGL-mediated TAG lipolysis protect from PUFA lipotoxicity. PMID: 29229414
  9. This report provides the first demonstration that Phosphatidylcholine-Isoprostanes are readily hydrolyzed by group IIA, V and X Secretory Phospholipases A2. PMID: 28528433
  10. Given an aberrant high level of sPLA2IIa in the tumor microenvironment that should be much higher than that in the blood, our findings support the notion that sPLA2IIa functions as a ligand for EGFR family receptors and supports CSC properties via HER/ERBB-elicited signaling, which may contribute to resistance to therapy and cancer progression PMID: 28440478
  11. the activity of human cPLA2alpha towards a multitude of glycerophospholipids species present in micelles or bilayers, was investigated. PMID: 27377346
  12. Mutational analysis of functional sites showed that both peroxidase and PLA2 active sites were necessary for mutant Prdx6 function, and that Prdx6 phosphorylation (at T177 residue) was essential for optimum PLA2 activity.Mutant Prdx6 at its Sumo1 sites escapes and abates this adverse process by maintaining its integrity and gaining function PMID: 28055018
  13. sPLA2-IIA activates Integrin alphaVbeta3 and Integrin alpha4beta1 in an allosteric manner. (Review) PMID: 27864802
  14. Leptin, at concentrations with minimal or no activating effects on astrocytoma cells, enhanced growth and migration promoted by low doses of sPLA2-IIA. sPLA2-IIA alone induced a transient phosphorylation pattern in the Src/ERK/Akt/mTOR/p70S6K/rS6 pathway through EGFR transactivation PMID: 28249041
  15. Molecular dynamics simulations reveal structural insights into inhibitor binding modes and functionality in human PLA2G2A. PMID: 28056488
  16. Hepatitis B virus can upregulate the expression of PLA2G2A, and serum levels of PLA2G2A are associated with the progression of hepatitis to liver cirrhosis and hepatocellular carcinoma. PMID: 28077172
  17. Dimethyl ester of bilirubin exhibits anti-inflammatory activity through inhibition of secretory phospholipase A2, lipoxygenase and cyclooxygenase. PMID: 27060751
  18. High expression of PLA2G2A was associated with poor therapeutic response and worse survival in patients with rectal cancer receiving neoadjuvant concurrent cheomoradiotherapy (CCRT). PMID: 25393083
  19. Data show that phospholipase A2 group IIA, V and X have different target/function related activity. PMID: 26711221
  20. Polyozellin might play an important role in the modulation of sPLA2-IIA expression and activity in response to the inflammatory diseases. PMID: 26659873
  21. Overexpression of sPLA2-IIA does not alter MCP-1 level at baseline, but could enhance the atherogenic effect of oxidized LDL in HASMCs, at least partly due to activation of Akt. PMID: 26488172
  22. These results suggest that the genetic ablation of iPLA2b increased iron uptake in the brain through the activation of IRP2 and upregulation of DMT1, which may be associated with mitochondrial dysfunction. PMID: 26506412
  23. IL-22 induced at an early stage of L. monocytogenes infection enhances innate immunity against L. monocytogenes in the liver by stimulating hepatocytes to produce PLA2G2A PMID: 26644377
  24. PLA2G2A was detected in all samples of endometriomas, but not in normal endometrium, and immunohistochemistry showed PLA2G2A-specific staining in epithelial cells of endometrioma paraffin sections. PMID: 25366587
  25. Results indicate that secreted phospholipase A2 IIA (sPLA2-IIA) as an enzyme working in concert with platelet microparticles (MPs) 12-lipoxygenase (12-LO) to promote internalization. PMID: 26106157
  26. Secretory PLA2 IIa expression can predict the clinical outcome of lung adenocarcinoma patients. PMID: 25317799
  27. Co-expression of PLA2G2A and COX-2 significantly correlated with the depth of invasion (p=0.004)and with TNM stage (p=0.04) of esophageal squamous cell carcinoma PMID: 25422234
  28. sPLA2 are secreted from ciliated cells and appear to induce mucin and cysLT secretion from goblet cells, strongly suggesting that airway goblet cells are proinflammatory effector cells. PMID: 25429648
  29. Studies indicate that the expression of secreted phospholipases A2 (sPLA2s), most notably the group IIA, III and X enzymes, is dysregulated in various malignant tissues. PMID: 25286228
  30. PLA2G2A levels increase in expectorations of cystic fibrosis patients in an age-dependent manner. PMID: 25290234
  31. AdPLA2 plays an important role in promoting tumorigenesis and disease progression by modulating the production of prostaglandins and may serve as a potential therapeutic target in TSC and LAM. PMID: 25347447
  32. Summarizing, Der p1 and Fel d1 involve phospholipase A2 enzymes in their action. PMID: 25247183
  33. The minor allele of rs11573156, is a dominant haplotype and is associated with the higher sPLA2-IIa levels. PMID: 25794429
  34. Activity of iPLbeta correlates inversely with the hydrophobicity of the phospholipid substrate. PMID: 25713085
  35. Secretory phospholipase A2 activity is raised in acute respiratory distress syndrome infants. PMID: 23883784
  36. Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrin alphaVbeta3, integrin alphavbeta1, and integrin alpha4beta1. PMID: 25398877
  37. women with metabolic syndrome demonstrated a low but positive correlation between sPLA2 and hsCRP levels PMID: 24521628
  38. Findings support the notion that sPLA2-IIa functions as a ligand for the EGFR family of receptors leading to an elevated HER/HER2-elicited signaling lung cancer cells. PMID: 24913497
  39. PLA2G2A gene polymorphisms may modify the risk of esophageal squamous cell carcinoma development PMID: 24641411
  40. hydrolysis of the mitochondrial membrane by sPLA2-IIA yields inflammatory mediators (ie, lysophospholipids, fatty acids, and mtDNA) that promote leukocyte activation PMID: 25082876
  41. This review presents evidence for pathophysiological roles of sPLA2 in the central nervous system and neurological diseases. PMID: 24113843
  42. Determined circulating levels of sPLA2-IIA, C-reactive protein (CRP), fibrinogen, factor VIII (FVIII), von Willebrand factor (vWF), and antithrombin as biomarkers of inflammation and coagulation in patients with various types of malignancies. PMID: 23722320
  43. Increased serum levels of serum amyloid a, PLA2G2, and C reactive protein were observed in patients with benign prostate hyperplasia, localized and metastasized prostate cancer in comparison to healthy individuals. PMID: 24061501
  44. Data indicate that the expression of genes encoding hGIIA, hGIII and hGX sPLA2s (PLA2G2A, PLA2G3 and PLA2G10, respectively) in breast tumour biopsies differs from that in normal tissues. PMID: 24508801
  45. two of these isoforms, sPLA2 IIA and sPLA2 IIF, localize to the upper stratum granulosum and increase in response to experimental barrier perturbation. PMID: 24269828
  46. Studied the role of human sPLA2-IIA, a bactericidal enzyme induced during acute inflammation, in innate immunity against GBS, and show clinical GBS isolates are highly sensitive to killing by sPLA2-IIA but not by human antimicrobial peptides. PMID: 23901095
  47. In a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile. PMID: 24115030
  48. Group IIA phospholipase A2 expression is an independent predictor of favorable outcome for patients with gastric cancer. PMID: 23664539
  49. Plasma PLA2 activities had approximately 70% specificity and sensitivity to detect cancer PMID: 23451150
  50. PLA2G2A may be a useful therapeutic target for a subset of gastric cancers PMID: 23852891

Show More

Hide All

Subcellular Location Cell membrane, Peripheral membrane protein, Secreted
Protein Families Phospholipase A2 family
Database Links

HGNC: 9031

OMIM: 172411

KEGG: hsa:5320

STRING: 9606.ENSP00000364252

UniGene: Hs.466804

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1